search
Back to results

Mechanism of EGR2 in Allergic Rhinitis

Primary Purpose

Rhinitis, Allergic

Status
Enrolling by invitation
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
EGR2
Sponsored by
Zu-xia Ma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Rhinitis, Allergic focused on measuring nasal polyps, chronic rhinosinusitis, atopic NPs, non-atopic NPs, EGR2

Eligibility Criteria

16 Years - 76 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: All patients were stopped by systemic or topical corticosteroid treatment at least one month before the study. Exclusion Criteria: Patients had NPs accompanied by choanal polyps, fungal nasal sinusitis, cystic fibrosis, acute upper airway upper infection or other systemic diseases.

Sites / Locations

  • Department of Central Laboratory of the Third Affiliated Hospital of ZunYi Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

immunohistochemistry

WestBlot

Arm Description

Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry

Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.

Outcomes

Primary Outcome Measures

expression of EGR2
expression of EGR2 were analyzed by immunohistochemistry and Western Blot

Secondary Outcome Measures

Full Information

First Posted
February 7, 2023
Last Updated
February 9, 2023
Sponsor
Zu-xia Ma
search

1. Study Identification

Unique Protocol Identification Number
NCT05724290
Brief Title
Mechanism of EGR2 in Allergic Rhinitis
Official Title
The Regulatory Mechanism of EGR2 Mediated by miR-150-5p on Allergic Rhinitis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
January 30, 2023 (Actual)
Primary Completion Date
February 1, 2023 (Actual)
Study Completion Date
May 5, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Zu-xia Ma

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
EGR2 may be a target for the treatment of nasal polyps.
Detailed Description
There is much debate about the etiology of nasal polyps, so the pathogenesis of nasal polyps still needs to be clarified. Surgery for noninflammatory nasal polyps may be better control, but surgery is not effective for recurrent sinusitis and nasal polyps. Therefore, more research is needed to determine the best targeted therapy for nasal polyps. We found that EGR2 expression was upregulated in CRSwNP patients with allergic rhinitis.In addition, the expression of EGR2 in CRSwNP mucosa was significantly higher than that in the control group, and the expression of EGR2 in CRSwNP with allergic rhinitis was higher than that in CRSwNP without allergic rhinitis. EGR2 may be involved in the pathogenesis of nasal polyps, and may also be related to the severity and recurrence of nasal polyps. EGR2 may be a target for the treatment of nasal polyps.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rhinitis, Allergic
Keywords
nasal polyps, chronic rhinosinusitis, atopic NPs, non-atopic NPs, EGR2

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
3 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
immunohistochemistry
Arm Type
Experimental
Arm Description
Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry
Arm Title
WestBlot
Arm Type
Experimental
Arm Description
Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.
Intervention Type
Genetic
Intervention Name(s)
EGR2
Intervention Description
We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
Primary Outcome Measure Information:
Title
expression of EGR2
Description
expression of EGR2 were analyzed by immunohistochemistry and Western Blot
Time Frame
one months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
76 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients were stopped by systemic or topical corticosteroid treatment at least one month before the study. Exclusion Criteria: Patients had NPs accompanied by choanal polyps, fungal nasal sinusitis, cystic fibrosis, acute upper airway upper infection or other systemic diseases.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yong Luo, Doctor
Organizational Affiliation
Zunyi Medical College
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Central Laboratory of the Third Affiliated Hospital of ZunYi Medical University
City
Zunyi
ZIP/Postal Code
563003
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Mechanism of EGR2 in Allergic Rhinitis

We'll reach out to this number within 24 hrs